Biogen in $1.25 bln deal with Forward Pharma to protect MS drug

Forward Pharma A/S

17/01/2017 13:02

Jan 17 (Reuters) - Biogen Inc  BIIB.O  said on Tuesday it 
would pay Forward Pharma A/S  FWP.O  $1.25 billion in cash to 
gain access to the Danish company's intellectual property as it 
seeks to protect the patent life of its flagship multiple 
sclerosis drug, Tecfidera. 
    The license agreement is subject to the approval of Forward 
Pharma shareholders.  urn:newsml:reuters.com:*:nBwbcVCJfa    
 
 (Reporting by Natalie Grover in Bengaluru; Editing by Ted Kerr) 
 ((natalie.grover@thomsonreuters.com)(;)(within U.S. +1 646 223 
8780, outside U.S. +91 99 1694 7070)(; Reuters 
Messaging:)(natalie.grover.thomsonreuters.com@reuters.net)) 
 
Keywords: BIOGEN DEALS/FORWARD PHARMA